Apixaban Medical Valley
Direct oral anticoagulant (Factor Xa inhibitor) — Film-coated tablets 2.5 mg
Quick Facts About Apixaban Medical Valley
Key Takeaways About Apixaban Medical Valley
- Proven stroke prevention: Apixaban is one of the most widely prescribed DOACs for reducing stroke risk in non-valvular atrial fibrillation, with superior efficacy and safety compared to warfarin in the landmark ARISTOTLE trial
- Lower bleeding risk than warfarin: Clinical studies show apixaban causes significantly less major bleeding and intracranial hemorrhage compared to traditional anticoagulants like warfarin
- No routine blood monitoring required: Unlike warfarin, apixaban does not require regular INR testing, making it more convenient for patients
- Reversible in emergencies: Andexanet alfa (Andexxa/Ondexxya) is an approved specific reversal agent that can rapidly reverse the anticoagulant effect of apixaban in emergency situations
- Never stop without medical advice: Abruptly discontinuing apixaban increases the risk of blood clots, stroke, and other thromboembolic events — always consult your physician before stopping
What Is Apixaban Medical Valley and What Is It Used For?
Apixaban Medical Valley is a prescription anticoagulant medication containing apixaban, which belongs to a class of drugs known as direct oral anticoagulants (DOACs) or novel oral anticoagulants (NOACs). It works by selectively inhibiting Factor Xa, a key enzyme in the blood clotting cascade, thereby reducing the formation of harmful blood clots.
Apixaban Medical Valley is a generic formulation of apixaban, the same active ingredient found in the widely recognized brand-name product Eliquis. As a Factor Xa inhibitor, apixaban represents a significant advancement in anticoagulation therapy compared to older medications such as warfarin. The drug was first approved by the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA) based on extensive clinical trial data demonstrating its efficacy and safety profile.
The medication is primarily prescribed for three key clinical indications. First, it is used for the prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF) who have one or more risk factors for stroke, such as prior stroke or transient ischemic attack (TIA), age 75 years or older, hypertension, diabetes mellitus, or symptomatic heart failure. Atrial fibrillation is the most common sustained cardiac arrhythmia, affecting approximately 33.5 million people worldwide, and is associated with a five-fold increased risk of stroke.
Second, Apixaban Medical Valley is indicated for the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE). DVT occurs when a blood clot forms in one of the deep veins, usually in the legs, while PE occurs when a clot travels to the lungs. Together, these conditions are referred to as venous thromboembolism (VTE), which is the third most common cardiovascular disease after myocardial infarction and stroke, affecting approximately 1 in 1,000 adults annually.
Third, the medication is approved for the prevention of recurrent DVT and PE in patients who have already been treated for these conditions. Extended anticoagulation therapy is often recommended because the risk of recurrence after a first unprovoked VTE event can be as high as 10% in the first year and up to 30% over five years without continued treatment.
How Does Apixaban Work?
Apixaban exerts its anticoagulant effect by directly and selectively binding to the active site of Factor Xa, both free Factor Xa and Factor Xa bound within the prothrombinase complex. Factor Xa plays a central role in the coagulation cascade, sitting at the convergence point of the intrinsic and extrinsic pathways. By inhibiting Factor Xa, apixaban prevents the conversion of prothrombin (Factor II) to thrombin (Factor IIa), which is the enzyme ultimately responsible for converting fibrinogen to fibrin — the structural protein that forms the meshwork of a blood clot.
Unlike heparin and low-molecular-weight heparins, apixaban does not require antithrombin III as a cofactor. This direct mechanism of action provides a more predictable anticoagulant response, with a rapid onset of action (peak plasma concentrations reached within 3–4 hours of oral administration) and a half-life of approximately 12 hours. The predictable pharmacokinetics and pharmacodynamics of apixaban eliminate the need for routine coagulation monitoring, a significant advantage over vitamin K antagonists like warfarin.
Apixaban Medical Valley is a generic version of Eliquis. Generic medicines undergo rigorous regulatory review to ensure they contain the same active ingredient, in the same dose, and demonstrate bioequivalence to the original product. This means they provide the same therapeutic effect at the same quality standards.
What Should You Know Before Taking Apixaban Medical Valley?
Before starting Apixaban Medical Valley, your physician must evaluate your individual bleeding risk, kidney and liver function, current medications, and medical history. This medication is not suitable for everyone, and certain conditions or drug combinations can significantly increase the risk of serious bleeding.
Contraindications
Apixaban Medical Valley must not be used in the following situations:
- Known hypersensitivity to apixaban or any of the excipients in the formulation
- Active clinically significant bleeding, such as gastrointestinal hemorrhage, intracranial bleeding, or any other major active bleed
- Hepatic disease associated with coagulopathy and clinically relevant bleeding risk, including severe hepatic impairment (Child-Pugh C)
- Lesions or conditions at significant risk of major bleeding, such as current or recent gastrointestinal ulceration, malignant neoplasms at high risk of bleeding, recent brain or spinal injury/surgery, recent intracranial hemorrhage, or known or suspected esophageal varices
- Concomitant treatment with any other anticoagulant agent, including unfractionated heparin, low-molecular-weight heparins, heparin derivatives, oral anticoagulants (warfarin, dabigatran, rivaroxaban, edoxaban), except under specific circumstances of switching anticoagulant therapy or when unfractionated heparin is given at doses necessary to maintain an open central venous or arterial catheter
Warnings and Precautions
Several important warnings apply to all patients taking apixaban:
As with all anticoagulants, apixaban increases the risk of bleeding, which can be serious and potentially life-threatening. Patients should be observed closely for signs and symptoms of bleeding, especially during the initiation of therapy and in patients with additional risk factors for hemorrhage. If severe bleeding occurs, treatment must be discontinued and the source of bleeding investigated.
Renal impairment: Approximately 27% of apixaban clearance is via the kidneys. While no dose adjustment is required for mild to moderate renal impairment alone, patients with severe renal impairment (creatinine clearance 15–29 mL/min) should use apixaban with caution, and certain dosing criteria may apply. Apixaban is not recommended in patients with creatinine clearance below 15 mL/min or in those on dialysis, as clinical data are limited.
Hepatic impairment: Apixaban is contraindicated in patients with severe hepatic impairment (Child-Pugh C). It should be used with caution in patients with mild or moderate hepatic impairment (Child-Pugh A or B), and coagulation testing may be considered in these patients. Patients with elevated liver enzymes (ALT/AST greater than 2 times the upper limit of normal) or total bilirubin greater than 1.5 times the upper limit of normal were excluded from clinical trials.
Spinal/epidural anesthesia or puncture: Patients receiving anticoagulants, including apixaban, who undergo neuraxial anesthesia (spinal or epidural) or spinal puncture are at risk of developing epidural or spinal hematoma, which can result in long-term or permanent paralysis. The risk is increased by the use of indwelling epidural catheters, concomitant use of medications affecting hemostasis (NSAIDs, platelet inhibitors, other anticoagulants), or by traumatic or repeated spinal puncture. Timing recommendations for catheter placement and removal in relation to apixaban dosing should be strictly followed.
Prosthetic heart valves: Apixaban has not been studied in patients with prosthetic heart valves and is not recommended for this population. Patients with mechanical prosthetic valves should continue to use vitamin K antagonists (warfarin) as their anticoagulant of choice.
Surgery and invasive procedures: Apixaban should be discontinued at least 48 hours before elective surgery or invasive procedures with a moderate or high risk of bleeding, or at least 24 hours before procedures with a low risk of bleeding. If surgery cannot be delayed, the increased risk of bleeding must be weighed against the urgency of the procedure.
Pregnancy and Breastfeeding
There are limited data on the use of apixaban in pregnant women. Animal studies have not shown direct or indirect harmful effects on reproductive toxicity at clinically relevant exposures. However, as a precautionary measure, apixaban is not recommended during pregnancy due to the inherent risk of hemorrhage.
It is not known whether apixaban or its metabolites are excreted in human breast milk. Available animal data have shown excretion of apixaban in milk. A risk to the breastfed infant cannot be excluded, and a decision must be made whether to discontinue breastfeeding or discontinue apixaban therapy, taking into account the benefit of therapy for the mother.
How Does Apixaban Medical Valley Interact with Other Drugs?
Apixaban is metabolized primarily by the CYP3A4 enzyme system and is a substrate for P-glycoprotein (P-gp). Strong inhibitors or inducers of both CYP3A4 and P-gp can significantly alter apixaban plasma levels, affecting its efficacy and safety. Always inform your healthcare provider about all medications you are taking.
Drug interactions with apixaban can be broadly categorized into those that increase bleeding risk by raising apixaban levels, those that decrease efficacy by reducing apixaban levels, and those that increase bleeding risk through additive pharmacological effects. Understanding these interactions is critical for safe and effective anticoagulation therapy.
Major Interactions
The following drug interactions are considered clinically significant and may require dose adjustment, close monitoring, or avoidance of the combination:
| Drug / Drug Class | Effect on Apixaban | Clinical Significance | Recommendation |
|---|---|---|---|
| Ketoconazole, Itraconazole | Strong CYP3A4 + P-gp inhibitor; significantly increases apixaban levels | High — increased bleeding risk | Not recommended; if unavoidable, reduce apixaban dose by 50% |
| Ritonavir, other HIV protease inhibitors | Strong CYP3A4 + P-gp inhibitor; increases apixaban exposure by approximately 2-fold | High — increased bleeding risk | Not recommended; if used, reduce apixaban dose by 50% |
| Rifampicin | Strong CYP3A4 + P-gp inducer; decreases apixaban exposure by approximately 54% | High — reduced anticoagulant efficacy | Avoid concomitant use |
| Carbamazepine, Phenytoin, Phenobarbital | Strong CYP3A4 inducers; substantially reduces apixaban levels | High — reduced anticoagulant efficacy | Avoid concomitant use |
| St. John's Wort (Hypericum perforatum) | Strong CYP3A4 inducer; reduces apixaban levels | High — reduced anticoagulant efficacy | Avoid concomitant use |
| Other anticoagulants (warfarin, heparin, enoxaparin) | Additive anticoagulant effect | High — greatly increased bleeding risk | Contraindicated (except during transitional switching) |
Minor Interactions
The following interactions are less severe but still clinically relevant and should be monitored:
| Drug / Drug Class | Effect | Recommendation |
|---|---|---|
| Aspirin (acetylsalicylic acid) | Additive bleeding risk due to antiplatelet effect | Use with caution; monitor for bleeding signs |
| NSAIDs (ibuprofen, naproxen, diclofenac) | Increased bleeding risk, especially gastrointestinal | Avoid long-term use; use the lowest effective dose for the shortest duration |
| Clopidogrel, Prasugrel, Ticagrelor | Additive bleeding risk due to antiplatelet effect | Only combine if clearly indicated (e.g., post-PCI); monitor closely |
| SSRIs, SNRIs (antidepressants) | May increase bleeding risk by affecting platelet function | Monitor for signs of bleeding |
| Diltiazem, Verapamil | Moderate CYP3A4/P-gp inhibitors; modest increase in apixaban levels | No dose adjustment required; monitor clinically |
What Is the Correct Dosage of Apixaban Medical Valley?
The standard dose of Apixaban Medical Valley depends on the clinical indication. For stroke prevention in atrial fibrillation, the recommended dose is 5 mg twice daily, with a reduced dose of 2.5 mg twice daily for patients meeting specific criteria. For DVT/PE treatment, the initial dose is 10 mg twice daily for 7 days, followed by 5 mg twice daily.
Dosing of apixaban must be carefully individualized based on the patient's clinical indication, age, body weight, renal function, and concomitant medications. The tablets should be swallowed whole with water and can be taken with or without food. For patients who are unable to swallow whole tablets, Apixaban Medical Valley tablets may be crushed and suspended in water, 5% dextrose, or apple juice, or mixed with applesauce and administered immediately.
Adults
| Indication | Initial Dose | Maintenance Dose | Duration |
|---|---|---|---|
| Stroke prevention in AF | 5 mg twice daily | 5 mg twice daily (or 2.5 mg twice daily if dose reduction criteria met) | Long-term / Lifelong |
| Treatment of DVT/PE | 10 mg twice daily for 7 days | 5 mg twice daily | At least 3–6 months |
| Prevention of recurrent DVT/PE | 2.5 mg twice daily | 2.5 mg twice daily | Determined by physician based on risk assessment |
| VTE prophylaxis after hip/knee replacement | 2.5 mg twice daily (starting 12–24 h post-surgery) | 2.5 mg twice daily | 32–38 days (hip) / 10–14 days (knee) |
The dose of apixaban should be reduced to 2.5 mg twice daily in patients with atrial fibrillation who meet at least two of the following three criteria: age ≥ 80 years, body weight ≤ 60 kg, or serum creatinine ≥ 1.5 mg/dL (133 micromoles/L). This dose reduction is based on pharmacokinetic modeling and clinical trial subgroup analyses showing higher drug exposure in these populations.
Children
Apixaban Medical Valley is not recommended for use in children and adolescents under 18 years of age. The safety and efficacy of apixaban in the pediatric population have not been established. There are no adequate data from clinical trials in this age group, and appropriate dosing has not been determined. Pediatric patients requiring anticoagulation should be managed with alternative therapies under specialist supervision.
Elderly
No general dose adjustment is required solely on the basis of age. However, elderly patients are at increased risk of bleeding and often have reduced renal function. In the context of stroke prevention in atrial fibrillation, age ≥ 80 years is one of the criteria that may trigger a dose reduction to 2.5 mg twice daily (when combined with at least one other criterion: body weight ≤ 60 kg or serum creatinine ≥ 1.5 mg/dL). Healthcare providers should carefully assess renal function and bleeding risk in elderly patients and adjust therapy accordingly.
Missed Dose
If you miss a dose of Apixaban Medical Valley, take it as soon as you remember on the same day. Do not take a double dose to make up for a forgotten dose. Take your next dose at the normally scheduled time and continue with your regular dosing schedule. It is important to take the medication consistently at approximately 12-hour intervals to maintain steady anticoagulant protection. If you are unsure what to do, contact your healthcare provider or pharmacist for guidance.
Overdose
There is no specific antidote for apixaban overdose in widespread clinical use, although andexanet alfa (marketed as Andexxa in the United States and Ondexxya in Europe) has been approved as a specific reversal agent. In case of overdose, seek immediate medical attention. Activated charcoal may be considered if administered within 2–3 hours of ingestion to reduce absorption. Hemodialysis is not expected to be effective in removing apixaban due to its high protein binding (approximately 87%). In the event of hemorrhagic complications, standard supportive measures should be initiated, including surgical hemostasis and blood product transfusion as needed.
Premature discontinuation of any oral anticoagulant, including apixaban, in the absence of adequate alternative anticoagulation increases the risk of thrombotic events. If anticoagulation with apixaban must be discontinued for a reason other than pathological bleeding or completion of therapy, coverage with another anticoagulant should be considered.
What Are the Side Effects of Apixaban Medical Valley?
The most common side effects of apixaban are related to its anticoagulant mechanism and include bleeding events of varying severity. Bruising, nosebleeds, and bleeding from gums are commonly reported. Serious bleeding events, while less frequent, can be life-threatening and require immediate medical attention.
Like all medicines, Apixaban Medical Valley can cause side effects, although not everybody gets them. The most important and frequently reported adverse reactions are hemorrhagic (bleeding) events, which is expected given the drug's mechanism of action. The safety profile of apixaban has been extensively characterized in large-scale clinical trials involving more than 30,000 patients, including the ARISTOTLE, AMPLIFY, ADVANCE, and AVERROES trials.
The frequency of side effects is classified according to international convention: very common (affects more than 1 in 10 patients), common (1 in 10 to 1 in 100), uncommon (1 in 100 to 1 in 1,000), rare (less than 1 in 1,000), and very rare (less than 1 in 10,000).
Common Side Effects
- Bruising (contusion, ecchymosis)
- Nosebleed (epistaxis)
- Bleeding from the gums (gingival bleeding)
- Blood in urine (hematuria)
- Heavy or irregular menstrual bleeding (menorrhagia, metrorrhagia)
- Anemia (reduced hemoglobin or hematocrit)
- Nausea
Uncommon Side Effects
- Gastrointestinal hemorrhage (rectal bleeding, vomiting blood)
- Hemorrhoidal bleeding
- Blood in stool (melena, occult blood positive)
- Hypotension (low blood pressure)
- Abnormal liver function tests (elevated transaminases)
- Skin rash or pruritus (itching)
- Post-procedural hemorrhage (wound bleeding after surgery)
- Conjunctival hemorrhage (eye bleeding)
- Hemoptysis (coughing up blood)
Rare Side Effects
- Intracranial hemorrhage (bleeding in the brain)
- Retroperitoneal hemorrhage
- Intraocular hemorrhage (bleeding inside the eye)
- Muscle hemorrhage
- Allergic reactions (hypersensitivity, angioedema, allergic edema)
- Thrombocytopenia (low platelet count)
Contact your doctor or emergency services immediately if you experience: unexplained prolonged or heavy bleeding, blood in vomit or vomit that looks like coffee grounds, black tarry stools, blood in urine, severe headache with no known cause, sudden weakness or numbness (especially on one side of the body), sudden vision changes, or signs of severe allergic reaction such as swelling of the face, lips, mouth, tongue, or throat, difficulty breathing, or collapse.
In the landmark ARISTOTLE trial comparing apixaban with warfarin in patients with atrial fibrillation, apixaban demonstrated a significantly lower rate of major bleeding (2.13% per year vs. 3.09% per year), intracranial hemorrhage (0.33% vs. 0.80% per year), and overall mortality compared to warfarin. This favorable bleeding profile is one of the key advantages of apixaban over traditional vitamin K antagonists.
It is important to note that minor bleeding events, such as bruising and gum bleeding, are expected consequences of anticoagulant therapy and do not necessarily require dose adjustment or discontinuation. However, any unusual or prolonged bleeding should be reported to your healthcare provider. Patients should also be aware that certain activities that increase the risk of physical injury should be approached with appropriate caution while taking anticoagulant therapy.
How Should You Store Apixaban Medical Valley?
Apixaban Medical Valley should be stored at room temperature below 30°C (86°F) in its original packaging to protect from moisture. Keep out of reach and sight of children. Do not use after the expiry date printed on the packaging.
Proper storage of medications is essential to ensure they remain effective and safe throughout their shelf life. Apixaban Medical Valley tablets should be stored in a dry place at temperatures not exceeding 30°C. The tablets should be kept in the original blister packaging until use to protect them from moisture. There are no special storage requirements regarding light exposure or refrigeration.
Do not use this medicine after the expiry date stated on the carton and blister after "EXP." The expiry date refers to the last day of that month. Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines you no longer use. These measures will help protect the environment and ensure medications are disposed of safely.
If you notice any visible changes in the appearance of the tablets (discoloration, crumbling, or unusual odor), do not take them and consult your pharmacist. Always check that the packaging is intact and has not been tampered with before use. When traveling, keep your medication in your carry-on luggage in its original packaging, along with a copy of your prescription or a letter from your doctor.
What Does Apixaban Medical Valley Contain?
Each film-coated tablet of Apixaban Medical Valley 2.5 mg contains 2.5 mg of the active substance apixaban, along with several inactive ingredients (excipients) that contribute to the tablet's stability, appearance, and absorption characteristics.
Active Ingredient
The active ingredient in Apixaban Medical Valley is apixaban, present at a dose of 2.5 mg per film-coated tablet. Apixaban is a synthetic small-molecule compound with the chemical formula C25H25N5O4 and a molecular weight of 459.5 g/mol. It appears as a white to pale yellow powder that is practically insoluble in water.
Inactive Ingredients (Excipients)
The following excipients are typically present in apixaban film-coated tablets. Note that the exact excipient composition may vary between manufacturers and between different formulations:
- Tablet core: Lactose anhydrous, microcrystalline cellulose, croscarmellose sodium, sodium lauryl sulfate, magnesium stearate
- Film coating: Lactose monohydrate, hypromellose, titanium dioxide (E171), triacetin, iron oxide yellow (E172)
Apixaban Medical Valley tablets contain lactose. Patients with rare hereditary problems of galactose intolerance, total lactase deficiency, or glucose-galactose malabsorption should not take this medicine. If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicinal product.
The film-coated tablets are designed for oral administration and should be swallowed whole. The film coating helps protect the active ingredient and facilitates swallowing. The 2.5 mg tablets are typically yellow and round in shape, with identifying markings that may vary by manufacturer. Always verify that the tablets you receive match the description provided in the package leaflet.
Frequently Asked Questions About Apixaban Medical Valley
Apixaban Medical Valley is used to prevent stroke and blood clots in patients with non-valvular atrial fibrillation, to treat deep vein thrombosis (DVT) and pulmonary embolism (PE), and to prevent recurrence of these conditions. It works by inhibiting Factor Xa, a key enzyme in the blood clotting cascade, thereby reducing the formation of blood clots.
Both Apixaban Medical Valley and Eliquis contain the same active ingredient, apixaban, at the same dose. Eliquis is the original brand-name product, while Apixaban Medical Valley is a generic equivalent that has been approved by regulatory authorities after demonstrating bioequivalence. Both provide the same therapeutic effect and meet the same quality standards.
While moderate alcohol consumption is not specifically contraindicated, excessive alcohol intake should be avoided because it can increase the risk of bleeding. Chronic heavy alcohol use may also affect liver function, potentially altering how apixaban is metabolized. Consult your doctor for personalized guidance based on your individual health status.
If you miss a dose, take it as soon as you remember on the same day. Do not take a double dose to compensate. Then take the next dose at your regular time. Consistent dosing at approximately 12-hour intervals is important for maintaining effective anticoagulation. If you are unsure, contact your pharmacist or doctor.
Yes. Andexanet alfa (Andexxa/Ondexxya) is a specific reversal agent approved for apixaban that can rapidly neutralize its anticoagulant effect in emergency situations such as life-threatening bleeding or urgent surgery. Prothrombin complex concentrate (PCC) may also be used in clinical settings where andexanet alfa is not available. In any case of significant bleeding, seek immediate medical attention.
Treatment duration depends on your condition. For atrial fibrillation, treatment is typically lifelong. For DVT or PE, the initial course is usually at least 3 to 6 months, with extended therapy possible depending on your recurrence risk and bleeding risk. For VTE prevention after joint replacement surgery, treatment lasts 10–38 days. Your doctor will determine the best duration based on your individual situation.
References and Medical Sources
All information in this article is based on internationally recognized medical guidelines, peer-reviewed research, and official regulatory documentation. The following sources have been used:
- Granger CB, et al. Apixaban versus Warfarin in Patients with Atrial Fibrillation (ARISTOTLE). New England Journal of Medicine. 2011;365(11):981-992. DOI: 10.1056/NEJMoa1107039
- Agnelli G, et al. Oral Apixaban for the Treatment of Acute Venous Thromboembolism (AMPLIFY). New England Journal of Medicine. 2013;369(9):799-808. DOI: 10.1056/NEJMoa1302507
- European Medicines Agency (EMA). Eliquis (apixaban) Summary of Product Characteristics. Last updated 2024.
- Hindricks G, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation. European Heart Journal. 2021;42(5):373-498. DOI: 10.1093/eurheartj/ehaa612
- January CT, et al. 2019 AHA/ACC/HRS Focused Update of the 2014 Guideline for the Management of Patients With Atrial Fibrillation. Journal of the American College of Cardiology. 2019;74(1):104-132.
- National Institute for Health and Care Excellence (NICE). Atrial fibrillation: diagnosis and management. NICE guideline [NG196]. Updated 2024.
- Connolly SJ, et al. Andexanet Alfa for Acute Major Bleeding Associated with Factor Xa Inhibitors. New England Journal of Medicine. 2016;375(12):1131-1141. DOI: 10.1056/NEJMoa1607887
- Kearon C, et al. Antithrombotic Therapy for VTE Disease: CHEST Guideline and Expert Panel Report. Chest. 2016;149(2):315-352.
- World Health Organization (WHO). WHO Model List of Essential Medicines, 23rd List. 2023.
- Lassen MR, et al. Apixaban versus Enoxaparin for Thromboprophylaxis after Hip Replacement (ADVANCE-3). New England Journal of Medicine. 2010;363(26):2487-2498.
Editorial Team
This article has been written and reviewed by the iMedic Medical Editorial Team, which includes specialists in cardiology, hematology, and clinical pharmacology. All content follows international guidelines and is based on evidence level 1A — the highest level of medical evidence from systematic reviews and meta-analyses of randomized controlled trials.
Independent panel of board-certified physicians who review all content according to international guidelines (ESC, AHA/ACC, NICE, WHO). Specialists in anticoagulation therapy and cardiovascular medicine.
All medical information follows the GRADE evidence framework. No commercial funding or pharmaceutical company sponsorship. Content reviewed and updated regularly based on the latest clinical evidence and guideline updates.